Celgene: A Promising Stock
With an attractive balance sheet, healthy revenue growth and a solid return on equity, biotech company Celgene looks like a promising stock buy.
Celgene
Six Stocks to Buy for Real Revenue Growth in 2011
The path to profits for most of Corporate America lately has been cutting costs rather than raising revenue. But a careful look reveals a few companies that are poised to deliver real revenue growth. We've found six with a plus: Their stocks look like bargains.
Pharmaceuticals Reveal Latest on Blood Disease Drugs
At the 52nd annual meeting of the American Society of Hematology, which wraps up Tuesday, Novartis, Celgene and Seattle Genetics revealed the latest news from their studies on blood diseases and cancers. But despite some positive results, all three had down days in the stock market.
Deutsche Bank Initiates Coverage of Biotech Stocks
Several biotech stocks were on the move Monday after Deutsche Bank started rating them. The bank's analyst, Robyn Karnauskas, took a generally wary view on the biotech sector, putting buy ratings only on Gilead and Dendreon.
Health-Care Sector Appears to Rally As Reform Chances Dim
President Obama can't be pleased by the loss of a Democratic Senate seat which jeopardizes passage of his cherished health-care reform. The news, however, appears to have fueled a mini stock rally in the health-care and pharma sectors wary of how any reform would affect their businesses. The uptrend is expected to continue.
Biotechs That Could Thrive with Health Reform
If the health care bills in Congress become law, the biotech sector may become one of the biggest beneficiaries. Here are six stocks and mutual funds that stand to gain the most from the changes.
Good Results for Celgene's Cancer Drug
Drug maker Celgene (CELG) says its multiple myeloma cancer pill reduced the risk of progression by half among newly diagnosed patients who used the drug and chemotherapy compared with those who only used chemotherapy.
